Statistik Asas
| LEI | 549300QODBI5C7YUJE09 |
| CIK | 819050 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Brickell Biotech Inc
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| May 8, 2024 |
FRTX / Fresh Tracks Therapeutics, Inc. / Exploration Capital, LLC - SCHEDULE 13D Activist Investment SC 13D 1 ea0205585-13dexplorfresh.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION, Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. N/A)* Fresh Tracks Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 10802T204 (CUSIP Number) Stephen Gustin Exploration Capital 250 East 200 South, Floor 16 S |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-21088 Fresh Tracks Therapeutics, Inc. (Exact name of registrant as speci |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-21088 FRESH TRACKS T |
|
| March 15, 2024 |
Exhibit 21.1 Subsidiaries of the Registrant (as of March 15, 2024) Name of Subsidiary Jurisdiction of Incorporation Brickell Subsidiary, Inc. Delaware |
|
| March 7, 2024 |
Exhibit 10.1 TERMINATION OF LICENSE AGREEMENT This Termination of License Agreement (this “Agreement”) is made and entered into as of March 1, 2024 by and between Carna Biosciences, Inc., a corporation organized under the laws of Japan (“Carna”) and Fresh Tracks Therapeutics, Inc. (f/k/a Brickell Biotech, Inc.), a Delaware corporation (“FRTX”). WHEREAS, Carna and FRTX are parties to that certain E |
|
| March 7, 2024 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) March 5, 2024 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 16, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) February 15, 2024 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (C |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| January 18, 2024 |
SC 13G/A 1 ea191783-13ga1explorfresh.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Fresh Tracks Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 10802T204 (CUSIP Number) January 17, 2024 (Date of Event Which Requires |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| January 5, 2024 |
PRELIMINARY COPY DATED JANUARY 5, 2024, SUBJECT TO COMPLETION PRELIMINARY COPY DATED JANUARY 5, 2024, SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) December 27, 2023 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (C |
|
| December 28, 2023 |
As filed with the Securities and Exchange Commission on December 28, 2023 As filed with the Securities and Exchange Commission on December 28, 2023 Registration No. |
|
| December 28, 2023 |
As filed with the Securities and Exchange Commission on December 28, 2023 As filed with the Securities and Exchange Commission on December 28, 2023 Registration No. |
|
| December 28, 2023 |
As filed with the Securities and Exchange Commission on December 28, 2023 As filed with the Securities and Exchange Commission on December 28, 2023 Registration No. |
|
| December 28, 2023 |
As filed with the Securities and Exchange Commission on December 28, 2023 As filed with the Securities and Exchange Commission on December 28, 2023 Registration No. |
|
| December 28, 2023 |
As filed with the Securities and Exchange Commission on December 28, 2023 As filed with the Securities and Exchange Commission on December 28, 2023 Registration No. |
|
| December 28, 2023 |
As filed with the Securities and Exchange Commission on December 28, 2023 As filed with the Securities and Exchange Commission on December 28, 2023 Registration No. |
|
| December 28, 2023 |
As filed with the Securities and Exchange Commission on December 28, 2023 As filed with the Securities and Exchange Commission on December 28, 2023 Registration No. |
|
| December 28, 2023 |
As filed with the Securities and Exchange Commission on December 28, 2023 As filed with the Securities and Exchange Commission on December 28, 2023 Registration No. |
|
| December 28, 2023 |
As filed with the Securities and Exchange Commission on December 28, 2023 As filed with the Securities and Exchange Commission on December 28, 2023 Registration No. |
|
| December 28, 2023 |
As filed with the Securities and Exchange Commission on December 28, 2023 As filed with the Securities and Exchange Commission on December 28, 2023 Registration No. |
|
| December 28, 2023 |
As filed with the Securities and Exchange Commission on December 28, 2023 As filed with the Securities and Exchange Commission on December 28, 2023 Registration No. |
|
| December 28, 2023 |
As filed with the Securities and Exchange Commission on December 28, 2023 As filed with the Securities and Exchange Commission on December 28, 2023 Registration No. |
|
| December 28, 2023 |
As filed with the Securities and Exchange Commission on December 28, 2023 As filed with the Securities and Exchange Commission on December 28, 2023 Registration No. |
|
| December 28, 2023 |
As filed with the Securities and Exchange Commission on December 28, 2023 As filed with the Securities and Exchange Commission on December 28, 2023 Registration No. |
|
| December 28, 2023 |
As filed with the Securities and Exchange Commission on December 28, 2023 As filed with the Securities and Exchange Commission on December 28, 2023 Registration No. |
|
| December 28, 2023 |
As filed with the Securities and Exchange Commission on December 28, 2023 As filed with the Securities and Exchange Commission on December 28, 2023 Registration No. |
|
| December 28, 2023 |
As filed with the Securities and Exchange Commission on December 28, 2023 As filed with the Securities and Exchange Commission on December 28, 2023 Registration No. |
|
| December 28, 2023 |
As filed with the Securities and Exchange Commission on December 28, 2023 As filed with the Securities and Exchange Commission on December 28, 2023 Registration No. |
|
| December 28, 2023 |
As filed with the Securities and Exchange Commission on December 28, 2023 As filed with the Securities and Exchange Commission on December 28, 2023 Registration No. |
|
| December 28, 2023 |
As filed with the Securities and Exchange Commission on December 28, 2023 As filed with the Securities and Exchange Commission on December 28, 2023 Registration No. |
|
| December 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) December 27, 2023 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (C |
|
| December 27, 2023 |
Exhibit 99.1 Fresh Tracks Therapeutics Announces Plan to Hold New Special Meeting of Stockholders on February 15th New record date expected to be January 11, 2024 Company intends to seek judicial dissolution if the liquidation and dissolution is not approved by Fresh Tracks’ stockholders at new special meeting, which would reduce the amount of cash distributable to stockholders BOULDER, CO – Decem |
|
| December 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| December 20, 2023 |
As filed with the Securities and Exchange Commission on December 20, 2023 As filed with the Securities and Exchange Commission on December 20, 2023 Registration No. |
|
| December 20, 2023 |
As filed with the Securities and Exchange Commission on December 20, 2023 As filed with the Securities and Exchange Commission on December 20, 2023 Registration No. |
|
| December 20, 2023 |
As filed with the Securities and Exchange Commission on December 20, 2023 As filed with the Securities and Exchange Commission on December 20, 2023 Registration No. |
|
| December 20, 2023 |
As filed with the Securities and Exchange Commission on December 20, 2023 As filed with the Securities and Exchange Commission on December 20, 2023 Registration No. |
|
| December 20, 2023 |
FRESH TRACKS THERAPEUTICS, INC. 2000 Central Avenue, Suite 100 Boulder, Colorado 80301 FRESH TRACKS THERAPEUTICS, INC. 2000 Central Avenue, Suite 100 Boulder, Colorado 80301 December 20, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 RE: Fresh Tracks Therapeutics, Inc. Withdrawal of Post-Effective Amendment No. 1 to Form S-1 Registration Statement File No. 333-237568 Ladies and Gentlemen: Pursuant to R |
|
| December 20, 2023 |
FRESH TRACKS THERAPEUTICS, INC. 2000 Central Avenue, Suite 100 Boulder, Colorado 80301 FRESH TRACKS THERAPEUTICS, INC. 2000 Central Avenue, Suite 100 Boulder, Colorado 80301 December 20, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 RE: Fresh Tracks Therapeutics, Inc. Withdrawal of Registration Statement on Form S-1 File No. 333-267254 Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the S |
|
| December 20, 2023 |
As filed with the Securities and Exchange Commission on December 20, 2023 As filed with the Securities and Exchange Commission on December 20, 2023 Registration No. |
|
| December 20, 2023 |
FRESH TRACKS THERAPEUTICS, INC. 2000 Central Avenue, Suite 100 Boulder, Colorado 80301 FRESH TRACKS THERAPEUTICS, INC. 2000 Central Avenue, Suite 100 Boulder, Colorado 80301 December 20, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 RE: Fresh Tracks Therapeutics, Inc. Withdrawal of Post-Effective Amendment No. 1 to Form S-3 Registration Statement File No. 333-236757 Ladies and Gentlemen: Pursuant to R |
|
| December 20, 2023 |
As filed with the Securities and Exchange Commission on December 20, 2023 As filed with the Securities and Exchange Commission on December 20, 2023 Registration No. |
|
| December 20, 2023 |
As filed with the Securities and Exchange Commission on December 20, 2023 As filed with the Securities and Exchange Commission on December 20, 2023 Registration No. |
|
| December 20, 2023 |
As filed with the Securities and Exchange Commission on December 20, 2023 As filed with the Securities and Exchange Commission on December 20, 2023 Registration No. |
|
| December 19, 2023 |
As filed with the Securities and Exchange Commission on December 18, 2023 As filed with the Securities and Exchange Commission on December 18, 2023 Registration No. |
|
| December 19, 2023 |
As filed with the Securities and Exchange Commission on December 18, 2023 As filed with the Securities and Exchange Commission on December 18, 2023 Registration No. |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) December 15, 2023 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (C |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| December 18, 2023 |
Exhibit 99.1 Fresh Tracks Therapeutics Announces its Common Stock will be Suspended from Trading on Nasdaq at Open of Business on December 19th Common stock expected to begin trading on over-the-counter market following suspension BOULDER, CO – December 18, 2023 – Fresh Tracks Therapeutics, Inc. (Nasdaq: FRTX) (“Fresh Tracks” or the “Company”) announced today receipt of a notice from Nasdaq statin |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) December 15, 2023 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (C |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) December 14, 2023 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (C |
|
| December 15, 2023 |
Exhibit 99.1 Fresh Tracks Therapeutics Announces Third Adjournment of Special Meeting of Stockholders Meeting adjourned to December 27, 2023 at 10 a.m. MT Fresh Tracks encourages all stockholders of record on October 17, 2023 who have not yet voted to do so by 11:59 p.m. Eastern Time on December 26, 2023 Company intends to seek judicial dissolution if the liquidation and dissolution is not approve |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) November 30, 2023 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (C |
|
| December 1, 2023 |
Exhibit 99.1 Fresh Tracks Therapeutics Announces Second Adjournment of Special Meeting of Stockholders Meeting adjourned to December 15, 2023 at 10 a.m. MT Fresh Tracks encourages all stockholders of record on October 17, 2023 who have not yet voted to do so by 11:59 p.m. Eastern Time on December 14, 2023 Company intends to seek judicial dissolution if the liquidation and dissolution is not approv |
|
| November 28, 2023 |
US10802T2042 / BRICKELL BIOTECH INC / Exploration Capital Fund, LP - SCHEDULE 13G Passive Investment SC 13G 1 ea189108-13gexploratfresh.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. N/A)* Fresh Tracks Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 10802T204 (CUSIP Number) November 17, 2023 (Date of Event Which Requires Filing of this Sta |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) November 16, 2023 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (C |
|
| November 17, 2023 |
Exhibit 99.1 Fresh Tracks Therapeutics Announces Adjournment of Special Meeting of Stockholders Meeting adjourned to November 30, 2023 at 10 a.m. MT Fresh Tracks encourages all stockholders of record on October 17, 2023 who have not yet voted to do so by 11:59 p.m. Eastern Time on November 29, 2023 Company intends to seek judicial dissolution if the liquidation and dissolution is not approved by F |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-21088 FRESH |
|
| November 13, 2023 |
3, 2023, by and between Fresh Tracks Therapeutics, Inc. and Exhibit 10.5 David R. McAvoy [***] [***] September 18, 2023 Re: Separation and Release Agreement Dear Mr. McAvoy: This letter sets forth the substance of the Separation and Release Agreement (the “Agreement”) that Fresh Tracks Therapeutics, Inc., f/k/a Brickell Biotech, Inc., the parent of Brickell Sub (“Brickell Parent”) and Brickell Subsidiary, Inc., d/b/a Brickell Biotech, Inc. (“Brickell Sub”) |
|
| November 13, 2023 |
, 2023, by and between Fresh Tracks Therapeutics, Inc. and Exhibit 10.7 Deepak Chadha [***] [***] August 16, 2023 Re: Separation and Release Agreement Dear Deepak: This letter sets forth the substance of the Separation and Release Agreement (the “Agreement”) that Fresh Tracks Therapeutics, Inc., f/k/a Brickell Biotech, Inc., the parent of Brickell Sub (“Brickell Parent”) and Brickell Subsidiary, Inc., d/b/a Brickell Biotech, Inc. (“Brickell Sub”), both be |
|
| November 13, 2023 |
3, 2023, by and between Fresh Tracks Therapeutics, Inc. and Exhibit 10.6 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”) is made October 3, 2023 (the “Effective Date”), by and between FRESH TRACKS THERAPEUTICS, INC., a Delaware corporation, with its principal place of business at Founder Central, 2000 Central Avenue, 100, Boulder, CO 80301 (hereafter “Corporation”) and MCAVOY LAW LLC, an Indiana domestic Limited Liability Company, with a p |
|
| November 13, 2023 |
Exhibit 99.1 Fresh Tracks Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update Cash and cash equivalents of approximately $11.5 million as of October 31, 2023 Special meeting of stockholders on November 16 seeking stockholder approval of the Dissolution and Plan of Dissolution If approved by stockholders, the Company estimates that cash distributions in the Disso |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) November 13, 2023 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (C |
|
| November 13, 2023 |
Amended and Restated Bylaws, effective as of September 18, 2023 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF FRESH TRACKS THERAPEUTICS, INC. ARTICLE I MEETINGS OF STOCKHOLDERS Section 1. Place of Meetings. All meetings of the stockholders shall be held at such place within or outside the State of Delaware as may be fixed from time to time by the Board of Directors or the chief executive officer, or if not so designated, at the registered office of the corporatio |
|
| October 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| October 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) October 10, 2023 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Co |
|
| October 10, 2023 |
Exhibit 10.2 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”) is made October 3, 2023 (the “Effective Date”), by and between FRESH TRACKS THERAPEUTICS, INC., a Delaware corporation, with its principal place of business at Founder Central, 2000 Central Avenue, 100, Boulder, CO 80301 (hereafter “Corporation”) and YONDER PARTNERS, LLC, a Colorado Limited Liability Company, with a prin |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) October 3, 2023 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Com |
|
| October 10, 2023 |
Exhibit 10.1 Andrew D. Sklawer [***] [***] September 18, 2023 Re: Separation and Release Agreement Dear Mr. Sklawer: This letter sets forth the substance of the Separation and Release Agreement (the “Agreement”) that Fresh Tracks Therapeutics, Inc., f/k/a Brickell Biotech, Inc., the parent of Brickell Sub (“Brickell Parent”) and Brickell Subsidiary, Inc., d/b/a Brickell Biotech, Inc. (“Brickell Su |
|
| October 4, 2023 |
PRELIMINARY COPY DATED OCTOBER 4, 2023, SUBJECT TO COMPLETION PRELIMINARY COPY DATED OCTOBER 4, 2023, SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 19, 2023 |
Plan of Dissolution of Fresh Tracks Therapeutics, Inc. Exhibit 2.1 PLAN OF LIQUIDATION AND DISSOLUTION OF FRESH TRACKS THERAPEUTICS, INC. This Plan of Liquidation and Dissolution (the “Plan”) is intended to accomplish the complete liquidation and dissolution of Fresh Tracks Therapeutics, Inc., a Delaware corporation (the “Company”), in accordance with Section 281(b) of the General Corporation Law of the State of Delaware (the “DGCL”). 1. Approval of P |
|
| September 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) September 18, 2023 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) ( |
|
| September 19, 2023 |
Amended and Restated Bylaws, effective as of Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF FRESH TRACKS THERAPEUTICS, INC. ARTICLE I MEETINGS OF STOCKHOLDERS Section 1. Place of Meetings. All meetings of the stockholders shall be held at such place within or outside the State of Delaware as may be fixed from time to time by the Board of Directors or the chief executive officer, or if not so designated, at the registered office of the corporatio |
|
| September 19, 2023 |
Exhibit 99.1 Fresh Tracks Therapeutics Announces Board Approval of Plan of Liquidation and Dissolution Company intends to make cash distributions currently estimated to be between $5 million and $7 million, or $0.84 to $1.17 per share, to shareholders following shareholder approval and the filing of the certificate of dissolution BOULDER, CO — September 19, 2023 — Fresh Tracks Therapeutics, Inc. ( |
|
| August 11, 2023 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF FRESH TRACKS THERAPEUTICS, INC. ARTICLE I MEETINGS OF STOCKHOLDERS Section 1. Place of Meetings. All meetings of the stockholders shall be held at such place within or outside the State of Delaware as may be fixed from time to time by the Board of Directors or the chief executive officer, or if not so designated, at the registered office of the corporatio |
|
| August 11, 2023 |
Exhibit 99.1 Fresh Tracks Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update Strengthened current cash position to approximately $15 million as of July 31, 2023 as a result of sale of future rights to event-based milestone and earnout payments on net sales of sofpironium bromide to Botanix SB Inc. Board continues to evaluate strategic alternatives for the Comp |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-21088 FRESH TRAC |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) August 11, 2023 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Com |
|
| July 25, 2023 |
Amended and Restated Bylaws, effective as of July 24, 2023 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF FRESH TRACKS THERAPEUTICS, INC. ARTICLE I MEETINGS OF STOCKHOLDERS Section 1. Place of Meetings. All meetings of the stockholders shall be held at such place within or outside the State of Delaware as may be fixed from time to time by the Board of Directors or the chief executive officer, or if not so designated, at the registered office of the corporatio |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) July 24, 2023 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 21, 2023 |
Exhibit 99.1 Fresh Tracks Announces $8.25 Million Buyout of Its Right to Receive Future Sofpironium Bromide Payments from Botanix – Strengthens cash position as Company continues to evaluate strategic options to maximize shareholder value – BOULDER, CO — July 21, 2023 — Fresh Tracks Therapeutics, Inc. (the “Company” or “Fresh Tracks”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company strivin |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) July 21, 2023 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 21, 2023 |
Exhibit 10.2 EXECUTION COPY SECOND AMENDMENT TO RIGHTS AGREEMENT This Second Amendment to Rights Agreement (this “Second Amendment”) is entered into as of July 21, 2023 by and among (a) Bodor Laboratories, Inc. (“BLI”), a Florida corporation having its principal place of business located at 4400 Biscayne Blvd., Miami, Florida 33137, (b) Brickell Subsidiary, Inc., d/b/a Brickell Biotech, Inc. (“Bri |
|
| July 21, 2023 |
Exhibit 10.1 EXECUTION COPY AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT This AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT (this “Amendment”), dated as of July 21, 2023 (the “Effective Date”), is made and entered into by and among Fresh Tracks Therapeutics, a Delaware corporation formerly known as Brickell Biotech, Inc. (“Fresh Tracks”), Brickell Subsidiary, Inc., a Delaware corporation d/b/a Bricke |
|
| May 10, 2023 |
BRE-BMR Flatiron VII LLC 4570 Executive Drive, Suite 400 • San Diego, CA 92121 Phone: (858) 485-9840 • Facsimile: (858) 485-9843 May 4, 2023 Fresh Tracks Therapeutics, Inc. |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-21088 FRESH TRA |
|
| May 10, 2023 |
Exhibit 99.1 Fresh Tracks Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update Reported positive topline results from SAD and MAD parts of Phase 1 study of lead DYRK1A inhibitor FRTX-02 in March 2023 Ongoing evaluation of strategic options to further develop FRTX-02 and maximize shareholder value Strengthened balance sheet with aggregate net proceeds of $6.6 mill |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) May 10, 2023 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 1, 2023 |
Exhibit 10.29 Monica E. Luchi, MD, FACR, MBA [***] [***] January 19, 2023 Re: Separation and Release Agreement Dear Monica, This letter sets forth the substance of the Separation and Release Agreement (the “Agreement”) that Fresh Tracks Therapeutics, Inc., f/k/a Brickell Biotech, Inc., the parent of Brickell Sub (“Brickell Parent”) and Brickell Subsidiary, Inc., d/b/a Brickell Biotech, Inc. (“Bric |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000- |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) April 21, 2023 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Comm |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) March 30, 2023 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Comm |
|
| March 30, 2023 |
Exhibit 21.1 Subsidiaries of the Registrant (as of March 30, 2023) Name of Subsidiary Jurisdiction of Incorporation Brickell Subsidiary, Inc. Delaware |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-21088 FRESH TRACKS T |
|
| March 30, 2023 |
Exhibit 10.27 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (“Agreement”) is made as of February 21, 2023 (the “Effective Date”) by and between FRESH TRACKS THERAPEUTICS, INC., f/k/a Brickell Biotech, Inc., the parent of Brickell Sub (“Brickell Parent”) and BRICKELL SUBSIDIARY, INC., d/b/a Brickell Biotech, Inc. (“Brickell Sub”), both being Delaware compa |
|
| March 30, 2023 |
Fresh Tracks Therapeutics, Inc. Employee Stock Purchase Plan Exhibit 10.34 FRESH TRACKS THERAPEUTICS, INC. EMPLOYEE STOCK PURCHASE PLAN 1. Purpose of the Plan. The purpose of this Fresh Tracks Therapeutics, Inc. Employee Stock Purchase Plan (the “Plan”) is to provide the employees of Fresh Tracks Therapeutics, Inc. (the “Company”) and its participating subsidiaries with a convenient means of purchasing shares of Company common stock from time to time at a d |
|
| March 30, 2023 |
Exhibit 99.1 Fresh Tracks Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Positive topline results from single and multiple ascending dose parts of the Phase 1 study of FRTX-02 support its continued development as a potential first-in-class, once-daily oral treatment for atopic dermatitis and/or other autoimmune diseases Continuing to evaluate |
|
| March 30, 2023 |
Exhibit 10.21 INDEMNITY AGREEMENT This Indemnification Agreement (“Agreement”) is made effective retroactive as of [insert date person became a director/officer/employee/agent of the Company for which indemnification will be provided], by and between Fresh Tracks Therapeutics, Inc., a Delaware corporation (the “Company”), and , a resident, with a domicile address of (“Indemnitee”). RECITALS WHEREA |
|
| March 30, 2023 |
Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Exchange Act Exhibit 4.8 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 23, 2023, Fresh Tracks Therapeutics, Inc. (the “Company,” “we,” “our” and “us”) maintained one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): its common stock, par value $0.01 per share (the “ |
|
| March 30, 2023 |
Exhibit 10.20 FIFTH AMENDMENT TO LEASE THIS FIFTH AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 29th day of December, 2022, by and between BRE-BMR FLATIRON VII LLC, a Delaware limited liability company (“Landlord,” as successor-in-interest to GPIF 5777 Flatiron LLC and BMC Properties, LLC), and FRESH TRACKS THERAPEUTICS, INC., a Delaware corporation (“Tenant,” formerly known as |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) March 8, 2023 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commi |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) March 7, 2023 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commi |
|
| March 7, 2023 |
Exhibit 99.1 Fresh Tracks Therapeutics Announces Positive Topline Results from Single and Multiple Ascending Dose Parts of Phase 1 Study of Oral DYRK1A Inhibitor FRTX-02 FRTX-02 was generally safe and well tolerated within the potential therapeutic dose range, meeting the study’s primary objectives Plasma concentrations within the potential therapeutic dose range were consistent with efficacious e |
|
| February 24, 2023 |
Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (“Agreement”) is made as of February 21, 2023 and effective as of fourteen (14) calendar days after such date (the “Effective Date”) by and between FRESH TRACKS THERAPEUTICS, INC., f/k/a Brickell Biotech, Inc., the parent of Brickell Sub (“Brickell Parent”) and BRICKELL SUBSIDIARY, INC., d/b/a Bri |
|
| February 24, 2023 |
Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (“Agreement”) is made as of February 21, 2023 (the “Effective Date”) by and between FRESH TRACKS THERAPEUTICS, INC., f/k/a Brickell Biotech, Inc., the parent of Brickell Sub (“Brickell Parent”) and BRICKELL SUBSIDIARY, INC., d/b/a Brickell Biotech, Inc. (“Brickell Sub”), both being Delaware compan |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) February 21, 2023 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (C |
|
| February 24, 2023 |
Form of Employee Retention Bonus Agreement Exhibit 10.3 February [x], 2023 Subject: Employee Retention Bonus Dear [Insert Employee Name]: We appreciate your dedication to Fresh Tracks Therapeutics, Inc. (the “Company”). Your contributions play a vital role in our success. Because of this, you are eligible to receive a bonus for your loyalty (“Retention Bonus”). The purpose of this Retention Bonus is to provide additional incentive and reco |
|
| February 22, 2023 |
Exhibit 10.1 February 21, 2023 Aaron Fox-Collis [***] [***] Re: Fresh Tracks Therapeutics, Inc. Amended and Restated Offer of Employment Dear Aaron: Fresh Tracks Therapeutics, Inc., f/k/a Brickell Biotech, Inc., a Delaware corporation (the “Company”), currently employs you pursuant to that certain Offer Letter dated as of June 30, 2020, and executed between you and the Company on July 1, 2020, wit |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) January 23, 2023 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction o |
|
| February 13, 2023 |
BBI / Brickell Biotech Inc / Ionic Ventures, LLC - SC 13G/A Passive Investment SC 13G/A 1 g083403sc-13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Fresh Tracks Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 10802T105 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check th |
|
| February 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) February 1, 2023 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Co |
|
| February 7, 2023 |
Exhibit 10.1 Robert B. Brown [***] [***] February 1, 2023 Re: Transition and Release Agreement Dear Rob: This letter sets forth the substance of the Transition and Release Agreement (the “Agreement”) that Fresh Tracks Therapeutics, Inc., f/k/a Brickell Biotech, Inc., the parent of Brickell Sub (“Brickell Parent”) and Brickell Subsidiary, Inc., d/b/a Brickell Biotech, Inc. (“Brickell Sub” and, toge |
|
| January 27, 2023 |
Exhibit 99.1 Fresh Tracks Therapeutics Appoints Andrew Sklawer as Chief Executive Officer Rob Brown to continue serving as a member of the Board of Directors and as a special advisor to the Company BOULDER, CO — January 27, 2023 — Fresh Tracks Therapeutics, Inc. (“Fresh Tracks” or the “Company”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company aiming to disrupt existing treatment paradigms |
|
| January 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) January 23, 2023 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Co |
|
| January 27, 2023 |
Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”) is made February 1, 2023 (the “Effective Date”), by and between FRESH TRACKS THERAPEUTICS, INC., a Delaware corporation, with its principal place of business at 5777 Central Avenue, Suite 102, Boulder, CO 80301 (hereafter “Corporation”) and DANCING BEAR CONSULTING, LLC, an Indiana LLC, with a principal place of business |
|
| November 14, 2022 |
Exhibit 10.3 FRESH TRACKS THERAPEUTICS, INC. 2020 OMNIBUS LONG-TERM INCENTIVE PLAN Restricted Stock Unit Award Agreement Fresh Tracks Therapeutics, Inc. (the ?Company?), pursuant to its 2020 Omnibus Long-Term Incentive Plan (the ?Plan?), hereby grants an award of Restricted Stock Units to you, the Participant named below. The terms and conditions of this Award are set forth in this Restricted Stoc |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-21088 FRESH |
|
| November 14, 2022 |
Exhibit 10.5 FRESH TRACKS THERAPEUTICS, INC. 2020 OMNIBUS LONG-TERM INCENTIVE PLAN Non-Qualified Stock Option Award Agreement Fresh Tracks Therapeutics, Inc. (the ?Company?), pursuant to its 2020 Omnibus Long-Term Incentive Plan (the ?Plan?), hereby grants an Option to purchase shares of the Company?s common stock to you, the Participant named below. The terms and conditions of the Option Award ar |
|
| November 14, 2022 |
Fresh Tracks Therapeutics, Inc. 2020 Omnibus Long-Term Incentive Plan, as amended on May 17, 2022 Exhibit 10.1 FRESH TRACKS THERAPEUTICS, INC. 2020 OMNIBUS LONG-TERM INCENTIVE PLAN, AS AMENDED ON MAY 17, 2022 TABLE OF CONTENTS Page SECTION 1 GENERAL 1 1.1. Purpose 1 1.2. Participation 1 1.3. Foreign Participants 1 1.4. Operation and Administration 1 1.5. History 1 SECTION 2 DEFINITIONS 2 SECTION 3 SHARES AND PLAN LIMITS 6 3.1. Shares of Stock and Other Amounts Subject to Plan 6 3.2. Adjustment |
|
| November 14, 2022 |
Exhibit 10.4 FRESH TRACKS THERAPEUTICS, INC. 2020 OMNIBUS LONG-TERM INCENTIVE PLAN Incentive Stock Option Award Agreement Fresh Tracks Therapeutics, Inc. (the ?Company?), pursuant to its 2020 Omnibus Long-Term Incentive Plan (the ?Plan?), hereby grants an Option to purchase shares of the Company?s common stock to you, the Participant named below. The terms and conditions of the Option Award are se |
|
| November 14, 2022 |
Amended and Restated Bylaws, as amended through September 6, 2022 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF FRESH TRACKS THERAPEUTICS, INC. ARTICLE I MEETINGS OF STOCKHOLDERS Section 1. Place of Meetings. All meetings of the stockholders shall be held at such place within or outside the State of Delaware as may be fixed from time to time by the Board of Directors or the chief executive officer, or if not so designated, at the registered office of the corporatio |
|
| November 14, 2022 |
Exhibit 10.6 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL ACKNOWLEDGMENT AND AGREEMENT RELATED TO ASSET PURCHASE AGREEMENT AND AMENDED AND RESTATED LICENSE AGREEMENT THIS ACKNOWLEDGMENT AND AGREEMENT (this ?Agreement?) is entered into as of Novembe |
|
| November 14, 2022 |
Fresh Tracks Therapeutics, Inc. Employee Stock Purchase Plan Exhibit 10.2 FRESH TRACKS THERAPEUTICS, INC. EMPLOYEE STOCK PURCHASE PLAN 1. Purpose of the Plan. The purpose of this Fresh Tracks Therapeutics, Inc. Employee Stock Purchase Plan (the ?Plan?) is to provide the employees of Fresh Tracks Therapeutics, Inc. (the ?Company?) and its participating subsidiaries with a convenient means of purchasing shares of Company common stock from time to time at a di |
|
| November 14, 2022 |
Exhibit 10.7 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL AMENDMENT TO RIGHTS AGREEMENT This Amendment to Rights Agreement (this ?Amendment?) is entered into as of November 10, 2022 by and among (a) Bodor Laboratories, Inc. (?BLI?), a Florida corpo |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) November 10, 2022 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (C |
|
| November 10, 2022 |
Exhibit 99.1 Fresh Tracks Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update Phase 1 study of FRTX-02 progressing well, with the SAD portion complete and MAD portion underway Remain on track to report SAD and MAD topline results from the Phase 1 study of FRTX-02 by early 2023 Advancing the development of FRTX-10 through early preclinical stage studies BOULDER, |
|
| September 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) September 20, 2022 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) ( |
|
| September 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) September 6, 2022 FRESH TRACKS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (C |
|
| September 8, 2022 |
Amended and Restated Certificate of Incorporation, as amended through September 6, 2022 Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF FRESH TRACKS THERAPEUTICS, INC. (Composite document reflecting amendments through September 6, 2022) ARTICLE I The name of the corporation is Fresh Track Therapeutics, Inc. ARTICLE II The address of its registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New |
|
| September 8, 2022 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF BRICKELL BIOTECH, INC. Brickell Biotech, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?Corporation?), hereby certifies as follows: FIRST: By unanimous written consent, the Board of Directors approved an amendment to the Restated Certificate of Incorporation, as |
|
| September 8, 2022 |
Amended and Restated Bylaws, as amended through September 6, 2022 Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF BRICKELL BIOTECHFRESH TRACKS THERAPEUTICS, INC. ARTICLE I MEETINGS OF STOCKHOLDERS Section 1. Place of Meetings. All meetings of the stockholders shall be held at such place within or outside the State of Delaware as may be fixed from time to time by the Board of Directors or the chief executive officer, or if not so designated, at the registered office o |
|
| September 7, 2022 |
September 7, 2022 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Fresh Tracks Therapeutics, Inc. Registration Statement on Form S-1 File Number 333-267254 Ladies and Gentlemen: Fresh Tracks Therapeutics, Inc. (the ?Company?) hereby requests that the effectiveness of the above-referenced registration statement on Form S-1 be accelerated so that it will be |
|
| September 6, 2022 |
September 6, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 RE: Brickell Biotech, Inc. Registration Statement on Form S-1 File No. 333-267254 To Whom It May Concern: Reference is made to the Registration Statement on Form S-1 (File No. 333-267254) filed by Brickell Biotech, Inc. (the ?Company?) with the Securities and |
|
| September 2, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Brickell Biotech, Inc. |
|
| September 2, 2022 |
As filed with the Securities and Exchange Commission on September 2, 2022 As filed with the Securities and Exchange Commission on September 2, 2022 Registration No. |
|
| September 1, 2022 |
Amended and Restated Bylaws, as currently in effect Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF BRICKELL BIOTECH, INC. ARTICLE I MEETINGS OF STOCKHOLDERS Section 1. Place of Meetings. All meetings of the stockholders shall be held at such place within or outside the State of Delaware as may be fixed from time to time by the Board of Directors or the chief executive officer, or if not so designated, at the registered office of the corporation. Sectio |
|
| September 1, 2022 |
Amended and Restated Certificate of Incorporation, as amended through July 5, 2022 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, OF BRICKELL BIOTECH, INC. (Composite document reflecting amendments through April 19July 5, 20212022) ARTICLE I The name of the corporation is Brickell Biotech, Inc. ARTICLE II The address of its registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, |
|
| September 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| September 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) August 30, 2022 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 23, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) August 19, 2022 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-21088 BRICKELL B |
|
| August 12, 2022 |
Amended and Restated Certificate of Incorporation, as amended through July 5, 2022 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, OF BRICKELL BIOTECH, INC. (Composite document reflecting amendments through April 19July 5, 20212022) ARTICLE I The name of the corporation is Brickell Biotech, Inc. ARTICLE II The address of its registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, |
|
| August 12, 2022 |
Amended and Restated Bylaws, as currently in effect EX-3.2 3 a2022063010qex32.htm EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF BRICKELL BIOTECH, INC. ARTICLE I MEETINGS OF STOCKHOLDERS Section 1. Place of Meetings. All meetings of the stockholders shall be held at such place within or outside the State of Delaware as may be fixed from time to time by the Board of Directors or the chief executive officer, or if not so designated, at the registe |
|
| August 11, 2022 |
EX-99.1 2 a20220630ex991pressrelease.htm EX-99.1 Exhibit 99.1 Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 Development of BBI-10 and next-generation kinase inhibitors a |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) August 11, 2022 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| July 29, 2022 |
Amended and Restated Bylaws, effective as of July 29, 2022 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF BRICKELL BIOTECH, INC. ARTICLE I MEETINGS OF STOCKHOLDERS Section 1. Place of Meetings. All meetings of the stockholders shall be held at such place within or outside the State of Delaware as may be fixed from time to time by the Board of Directors or the chief executive officer, or if not so designated, at the registered office of the corporation. Sectio |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) July 28, 2022 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| July 20, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) July 19, 2022 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| July 20, 2022 |
Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement BOULDER, CO ? July 20, 2022 ? Brickell Biotech, Inc. (?Brickell?) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, to |
|
| July 5, 2022 |
Certificate of Elimination, dated July 5, 2022 Exhibit 3.2 BRICKELL BIOTECH, INC. CERTIFICATE OF ELIMINATION OF SERIES A PREFERRED STOCK Pursuant to the provisions of Section 151(g) of the General Corporation Law of the State of Delaware, it is hereby certified that: FIRST: The name of the corporation (hereinafter referred to as the ?Corporation?) is Brickell Biotech, Inc. On May 25, 2022, the Corporation filed a Certificate of Designation wit |
|
| July 5, 2022 |
Certificate of Amendment to the Restated Certificate of Incorporation, dated July 1, 2022 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF BRICKELL BIOTECH, INC. Brickell Biotech, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?Corporation?), hereby certifies as follows: FIRST: By unanimous written consent, the Board of Directors approved a proposed amendment to the Restated Certificate of Incorporat |
|
| July 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) June 30, 2022 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| July 5, 2022 |
Exhibit 99.1 Brickell Biotech Announces 1-For-45 Reverse Stock Split ? Common stock will begin trading on a split-adjusted basis on July 5, 2022 ? BOULDER, CO ? July 1, 2022 ? Brickell Biotech, Inc. (?Brickell? or the ?Company?) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the tr |
|
| June 23, 2022 |
As filed with the Securities and Exchange Commission on June 23, 2022 As filed with the Securities and Exchange Commission on June 23, 2022 Registration No. |
|
| June 23, 2022 |
As filed with the Securities and Exchange Commission on June 23, 2022 As filed with the Securities and Exchange Commission on June 23, 2022 Registration No. |
|
| June 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| June 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| June 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) June 14, 2022 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| June 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) June 1, 2022 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 27, 2022 |
PRELIMINARY COPY DATED MAY 27, 2022, SUBJECT TO COMPLETION PRELIMINARY COPY DATED MAY 27, 2022, SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) May 25, 2022 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 25, 2022 |
Certificate of Designation of Series A Preferred Stock, dated May Exhibit 3.1 BRICKELL BIOTECH, INC. CERTIFICATE OF DESIGNATION OF SERIES A PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Brickell Biotech, Inc., a Delaware corporation (the ?Corporation?), that the following resolution was duly adopted by the board of directors of the Corporation (the ?Board of Direc |
|
| May 25, 2022 |
Exhibit 10.1 It is the responsibility of any investor purchasing these securities to satisfy itself as to full observance of the laws of any relevant territory outside the United States in connection with any such purchase, including obtaining any required governmental or other consents or observing any other applicable requirements. We are not making an offer to sell these securities in any juris |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. |
|
| May 24, 2022 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) BRICKELL BIOTECH, INC. |
|
| May 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) May 17, 2022 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 17, 2022 |
Brickell Biotech, Inc. 2020 Omnibus Long-Term Incentive Plan, as amended through May 17, 2022 Exhibit 10.1 BRICKELL BIOTECH, INC. 2020 OMNIBUS LONG-TERM INCENTIVE PLAN, AS AMENDED ON MAY 17, 2022 TABLE OF CONTENTS Page SECTION 1 GENERAL 1 1.1. Purpose 1 1.2. Participation 1 1.3. Foreign Participants 1 1.4. Operation and Administration 1 1.5. History 1 SECTION 2 DEFINITIONS 2 SECTION 3 SHARES AND PLAN LIMITS 6 3.1. Shares of Stock and Other Amounts Subject to Plan 6 3.2. Adjustments 8 3.3. |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-21088 BRICKELL |
|
| May 12, 2022 |
Exhibit 99.1 Brickell Biotech Reports First Quarter 2022 Financial Results and Provides Corporate Update Completed sale of sofpironium bromide to Botanix Pharmaceuticals for up to $9 million in upfront and potential near-term regulatory milestone payments, $168 million in potential future regulatory and sales milestone payments, plus tiered earnout payments on net sales Sale reflects Brickell?s ne |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) May 12, 2022 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 12, 2022 |
Brickell Biotech, Inc. Up to $15,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-254037 PROSPECTUS SUPPLEMENT (To Prospectus Supplement and Prospectus dated March 17, 2021) Brickell Biotech, Inc. Up to $15,000,000 Common Stock This prospectus supplement amends and supplements the information in our prospectus and prospectus supplement, each dated March 17, 2021 (File No. 333-254037), or collectively, the ?Prospectus.? This |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| May 3, 2022 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL ASSET PURCHASE AGREEMENT among BRICKELL BIOTECH, INC., BRICKELL SUBSIDIARY, INC., BOTANIX SB INC. and solely for purposes of Article I, Section 5.10, Article VI and Article VII BOTANIX PHARM |
|
| May 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) May 3, 2022 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 3, 2022 |
EX-99.1 2 a202205038kex991am.htm EX-99.1 Exhibit 99.1 Brickell Biotech Announces Adjournment of Annual Meeting of Stockholders Meeting adjourned to May 17, 2022 at 10 a.m. MT Brickell encourages all stockholders of record on March 7, 2022 who have not yet voted to do so by 11:59 p.m. Eastern Time on May 16, 2022 BOULDER, CO — May 3, 2022 — Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell”) announce |
|
| May 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) May 3, 2022 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 3, 2022 |
Exhibit 99.1 Brickell Biotech Announces Sale of Sofpironium Bromide to Botanix Pharmaceuticals Deal includes up to $9 million in upfront and potential near-term regulatory milestone payments, $168 million in potential future regulatory and sales milestone payments, plus tiered earnout payments on net sales to Brickell Sale reflects Brickell?s strategic shift into the immunology and inflammation fi |
|
| May 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| May 3, 2022 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL RIGHTS AGREEMENT This Rights Agreement (?Rights Agreement?), effective as of May 3, 2022 (the ?Effective Date?), is made by and among (a) Bodor Laboratories, Inc. (?BLI?), a Florida corporat |
|
| May 3, 2022 |
2022, by and between Botanix SB Inc. and Brickell Biotech, Inc. Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL TRANSITION SERVICES AGREEMENT This TRANSITION SERVICES AGREEMENT (this ?Agreement?) is entered into effective as of the 3rd day of May 2022 (the ?Effective Date?) by and between Botanix SB I |
|
| March 22, 2022 |
DEF 14A 1 a20220322def-14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as |
|
| March 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) March 15, 2022 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 15, 2022 |
Exhibit 99.1 Brickell Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Broadened strategic focus and expanded pipeline in immunology and inflammation following acquisition of rights to BBI-02, a potential first-in-class oral DYRK1A inhibitor, a portfolio of novel STING inhibitors, and a next-generation kinase inhibitor platform On track to initiate |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-21088 BRICKELL BIOTECH, INC. (E |
|
| March 15, 2022 |
Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Exchange Act Exhibit 4.10 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, Brickell Biotech, Inc. (the ?Company,? ?we,? ?our? and ?us?) maintained one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): its common stock, par value $0.01 per share (the ?Commo |
|
| March 15, 2022 |
EX-21.1 3 a2021123110kex211.htm EX-21.1 Exhibit 21.1 Subsidiaries of the Registrant (as of March 15, 2022) Name of Subsidiary Jurisdiction of Incorporation Brickell Subsidiary, Inc. Delaware |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| February 3, 2022 |
BBI / Brickell Biotech Inc / Ionic Ventures, LLC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Brickell Biotech, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 10802T105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| February 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) February 2, 2022 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 2, 2022 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL Execution Version EXCLUSIVE LICENSE AGREEMENT by and between CARNA BIOSCIENCES, INC. and BRICKELL BIOTECH, INC. EXCLUSIVE LICENSE AGREEMENT This Exclusive License Agreement (this ?Agreement? |
|
| February 2, 2022 |
Exhibit 99.1 Brickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune and Inflammatory Diseases from Carna Biosciences Lead STING inhibitor candidate, BBI-10, demonstrated dose-dependent cytokine reduction in nonclinical in vitro and in vivo studies providing strong proof-of-mechanism Agreement enhances Brickell?s pipeline in immunology and infl |
|
| December 14, 2021 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) December 14, 2021 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 9, 2021 |
Employment Agreement, dated August 26, 2021, by and between Brickell Biotech, Inc. and Monica Luchi Exhibit 10.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (?Agreement?) is made as of August 20, 2021, 2021(?Effective Date?) by and between BRICKELL BIOTECH, INC., a Delaware Company with a principal business address located at 5777 Central Avenue, Suite 102, Boulder, CO 80301 (the ?Company?), and Monica E. Luchi, MD, FACR, MBA, a New Jersey resident, with an address of [***] (the ?Executive?). |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-21088 BRICK |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) November 9, 2021 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 9, 2021 |
EX-99.1 2 a20210930ex991pressrelease.htm EX-99.1 Exhibit 99.1 Brickell Biotech Reports Third Quarter 2021 Financial Results and Provides Corporate Update Announced positive topline results from the Phase 3 pivotal clinical studies of sofpironium bromide gel, 15% in primary axillary hyperhidrosis patients; plan to submit a New Drug Application (NDA) to the FDA in mid-2022 Development of DYRK1A inhi |
|
| November 3, 2021 |
BBI / Brickell Biotech Inc / Ionic Ventures, LLC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Brickell Biotech, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 10802T105 (CUSIP Number) October 28, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| November 1, 2021 |
Exhibit 1.1 Execution Version 26,316,000 Shares of Common Stock BRICKELL BIOTECH, INC. UNDERWRITING AGREEMENT October 28, 2021 William Blair & Company, L.L.C. as Representative of the several Underwriters named on Schedule I hereto c/o William Blair & Company, L.L.C. The William Blair Building 150 North Riverside Plaza Chicago, IL 60606 Ladies and Gentlemen: Brickell Biotech, Inc., a Delaware corp |
|
| November 1, 2021 |
Brickell Biotech Prices Public Offering of Common Stock Exhibit 99.2 Brickell Biotech Prices Public Offering of Common Stock Boulder, CO ? October 28, 2021 ? Brickell Biotech, Inc. (Nasdaq: BBI) (?Brickell?), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, announced today the pr |
|
| November 1, 2021 |
Brickell Biotech Announces Proposed Underwritten Public Offering of Common Stock Exhibit 99.1 Brickell Biotech Announces Proposed Underwritten Public Offering of Common Stock BOULDER, CO ? October 27, 2021 ? Brickell Biotech, Inc. (Nasdaq: BBI) (?Brickell?), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating disease |
|
| November 1, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) October 27, 2021 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 28, 2021 |
26,316,000 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-254037 PROSPECTUS SUPPLEMENT (To Prospectus dated March 17, 2021) 26,316,000 Shares of Common Stock We are offering 26,316,000 shares of our common stock, $0.01 par value per share. Our common stock is listed on the Nasdaq Capital Market under the symbol ?BBI.? On October 26, 2021, the last reported sale price of our common stock as reported on |
|
| October 27, 2021 |
SUBJECT TO COMPLETION, DATED OCTOBER 27, 2021 Filed pursuant to Rule 424(b)(5) Registration No. 333-254037 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell and are not soliciting an |
|
| October 7, 2021 |
Investor presentation dated October 7, 2021 Exhibit 99.1 |
|
| October 7, 2021 |
Exhibit 99.1 Brickell Biotech Announces Positive Topline Results, Achieving Statistical Significance on all Primary and Secondary Endpoints, from Both U.S. Phase 3 Pivotal Clinical Studies of Sofpironium Bromide Gel, 15% in Primary Axillary Hyperhidrosis Patients Sofpironium bromide gel, 15% was generally well-tolerated Plan to submit a New Drug Application (NDA) to the FDA in mid-2022 Management |
|
| October 7, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) October 7, 2021 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| October 7, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) October 7, 2021 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| September 1, 2021 |
Exhibit 99.1 Brickell Biotech Acquires Exclusive Rights to Phase 1-Ready DYRK1A Inhibitor Program and Novel Platform Targeting Autoimmune and Inflammatory Diseases Expect to initiate Phase 1 clinical study of lead DYRK1A inhibitor program, BBI-02, a potential first-in-class oral treatment for autoimmune and inflammatory diseases, in 2022 Acquisition includes rights to platform of DYRK1A inhibitors |
|
| September 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) August 27, 2021 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| September 1, 2021 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL LICENSE AND DEVELOPMENT AGREEMENT by and between VORONOI INC. and BRICKELL BIOTECH, INC. LICENSE AND DEVELOPMENT AGREEMENT This LICENSE AND DEVELOPMENT AGREEMENT (the ?Agreement?) is entered |
|
| August 12, 2021 |
Exhibit 10.1 FOURTH AMENDMENT TO LEASE THIS FOURTH AMENDMENT TO LEASE (?Amendment?), dated as of June 17, 2021, is entered into by and between GPIF 5777 FLATIRON LLC, a Delaware limited liability company (?Landlord?), and BRICKELL BIOTECH, INC., a Delaware corporation (?Tenant?). Recitals: A.Landlord?s predecessor in interest and Tenant entered into a written lease agreement (?Base Lease?) dated A |
|
| August 12, 2021 |
Exhibit 99.1 Brickell Biotech Reports Second Quarter 2021 Financial Results and Provides Corporate Update Final patient has completed the Phase 3 pivotal Cardigan I study; Enrollment completed in Phase 3 pivotal Cardigan II study - - - Topline results for Phase 3 pivotal Cardigan I and Cardigan II studies expected to be reported in Q4 2021 - - - Recent $8.1 million capital raise expected to fund o |
|
| August 12, 2021 |
Exhibit 10.4 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED BRICKELL-KAKEN AMENDMENT TO CLINICAL SUPPLY AGREEMENT AND LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This Amendment to the Clinical Supply Agreement and License, Development, and Comme |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) August 12, 2021 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-21088 BRICKELL B |
|
| July 22, 2021 |
Brickell Biotech Increases Previously Announced Bought Deal Offering of Common Stock to $7.0 Million EX-99.2 5 a202107228kex992.htm EX-99.2 Exhibit 99.2 Brickell Biotech Increases Previously Announced Bought Deal Offering of Common Stock to $7.0 Million BOULDER, CO – July 19, 2021 – Brickell Biotech, Inc. (Nasdaq: BBI) (the “Company” or “Brickell”), clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating |
|
| July 22, 2021 |
BBI / Brickell Biotech Inc / Ionic Ventures, LLC - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Brickell Biotech, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 10802T105 (CUSIP Number) July 22, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| July 22, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) July 19, 2021 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| July 22, 2021 |
Exhibit 1.1 11,290,323 Shares of Common Stock BRICKELL BIOTECH, INC. AMENDED AND RESTATED UNDERWRITING AGREEMENT July 19, 2021 H.C. Wainwright & Co., LLC as Representative of the several Underwriters named on Schedule I hereto c/o H.C. Wainwright & Co., LLC 430 Park Avenue, 4th Floor New York, NY 10022 Ladies and Gentlemen: Brickell Biotech, Inc., a Delaware corporation (the ?Company?), proposes, |
|
| July 22, 2021 |
Brickell Biotech Announces $5.0 Million Bought Deal Offering of Common Stock Exhibit 99.1 Brickell Biotech Announces $5.0 Million Bought Deal Offering of Common Stock BOULDER, CO ? July 19, 2021 ? Brickell Biotech, Inc. (Nasdaq: BBI) (?Brickell? or the ?Company?), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it has entered into an u |
|
| July 22, 2021 |
Exhibit 99.3 Brickell Biotech Announces Closing of $8.05 Million Bought Deal Offering of Common Stock, Including Full Exercise of the Underwriter?s Option to Purchase Additional Shares BOULDER, CO ? July 22, 2021 ? Brickell Biotech, Inc. (Nasdaq: BBI) (the ?Company? or ?Brickell?), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics |
|
| July 20, 2021 |
Brickell Biotech Increases Previously Announced Bought Deal Offering of Common Stock to $7.0 Million Free Writing Prospectus dated July 19, 2021 Filed pursuant to Rule 433 Relating to the Preliminary Prospectus Supplement dated July 19, 2021 Registration Statement No. |
|
| July 20, 2021 |
11,290,323 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-254037 PROSPECTUS SUPPLEMENT (To Prospectus dated March 17, 2021) 11,290,323 Shares of Common Stock We are offering 11,290,323 shares of our common stock, $0.01 par value per share. Our common stock is listed on the Nasdaq Capital Market under the symbol “BBI.” On July 16, 2021, the last reported sale price of our common stock as reported on th |
|
| July 19, 2021 |
Brickell Biotech Announces $5.0 Million Bought Deal Offering of Common Stock Free Writing Prospectus dated July 19, 2021 Filed pursuant to Rule 433 Relating to the Preliminary Prospectus Supplement dated July 19, 2021 Registration Statement No. |
|
| July 19, 2021 |
SUBJECT TO COMPLETION, DATED JULY 19, 2021 Filed pursuant to Rule 424(b)(5) Registration No. 333-254037 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell and are not soliciting an |
|
| June 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) June 16, 2021 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 14, 2021 |
As filed with the Securities and Exchange Commission on May 14, 2021 As filed with the Securities and Exchange Commission on May 14, 2021 Registration No. |
|
| May 14, 2021 |
As filed with the Securities and Exchange Commission on May 14, 2021 Registration No. |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) May 13, 2021 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 13, 2021 |
Exhibit 99.1 Brickell Biotech Reports First Quarter 2021 Financial Results and Provides Corporate Update Completed enrollment in Phase 3 pivotal Cardigan I study and exceeded 70% enrollment in Phase 3 pivotal Cardigan II study - - - Topline results for Phase 3 pivotal Cardigan I and Cardigan II studies expected in Q4 2021 - - - Presented results from Phase 3 open-label, long-term safety study of s |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-21088 BRICKELL |
|
| April 23, 2021 |
Investor presentation dated April 23, 2021 Exhibit 99.2 |
|
| April 23, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) April 23, 2021 BRICKELL BIOTECH, INC. (Exact name of Registrant as specified in its charter) Delaware 000-21088 93-0948554 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 23, 2021 |
Exhibit 99.1 Brickell Biotech Reports Results from U.S. Phase 3 Open-Label, Long-Term Safety Study on Chronic Use of Sofpironium Bromide Gel as a Potential Treatment for Primary Axillary Hyperhidrosis Daily treatment with sofpironium bromide gel was generally well-tolerated over 48 weeks of treatment - - - Efficacy assessments showed a clinically meaningful and sustained improvement in sweat sever |
|
| April 19, 2021 |
Brickell Biotech, Inc. 2020 Omnibus Long-Term Incentive Plan, as amended through April 19, 2021 EX-10.1 4 a202104198kex101.htm EX-10.1 Exhibit 10.1 BRICKELL BIOTECH, INC. 2020 OMNIBUS LONG-TERM INCENTIVE PLAN, AS AMENDED ON APRIL 19, 2021 TABLE OF CONTENTS Page SECTION 1 GENERAL 1 1.1. Purpose 1 1.2. Participation 1 1.3. Foreign Participants 1 1.4. Operation and Administration 1 1.5. History 2 SECTION 2 DEFINITIONS 2 SECTION 3 SHARES AND PLAN LIMITS 6 3.1. Shares of Stock and Other Amounts S |
|
| April 19, 2021 |
Amended and Restated Certificate of Incorporation, as amended through April 19, 2021 Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, OF BRICKELL BIOTECH, INC. (Composite document reflecting amendments through April 19, 2021) ARTICLE I The name of the corporation is Brickell Biotech, Inc. ARTICLE II The address of its registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, Delaware 1 |
